Brad Hornberger

Brad Hornberger

Auto-generated profile, based on publicly available information

Brad Hornberger

Department of Urology, UT Southwestern Medical Center, Dallas, TX

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
YFYuval Freifeld
Yuval Freifeld
YXYin Xi
Yin Xi
NPNiccolo Passoni
Niccolo Passoni
SWSolomon Woldu
Solomon Woldu
BHBrad Hornberger
Brad Hornberger
DCDaniel Costa
Daniel Costa

1 August 2017 in Urology
Verified
Journal Article
Closed access
JLJoshua P. Langston
Joshua P. Langston
RDRichard Duszak
Richard Duszak
VOVenetia L. Orcutt
Venetia L. Orcutt
HSHeather Schultz
Heather Schultz
BHBrad Hornberger
Brad Hornberger
MNMatthew E. Nielsen
Matthew E. Nielsen

18 March 2017 in Urology Practice
Verified
Journal Article
Open access
PDF file
SWSolomon L. Woldu
Solomon L. Woldu
RHRyan C. Hutchinson
Ryan C. Hutchinson
NSNirmish Singla
Nirmish Singla
BHBrad Hornberger
Brad Hornberger
CRClaus G. Roehrborn
Claus G. Roehrborn
YLYair Lotan
Yair Lotan
A number of strategies have been attempted to minimize the risk of infection following transrectal prostate procedures. We report our prospective efforts at augmenting our prophylaxis strategy over time. Since 2010 we have prospectively monitored infections after transrectal prostate procedures and changed our prophylaxis regimen twice in an effort to respond to increases in infectious complications. In 2011 we added a single dose of intramuscular aminoglycoside to our prophylaxis regimen of fluoroquinolones or trimethoprim-sulfamethoxazole. In 2015 we began performing formalin needle tip disinfection before each biopsy and screening high risk patients for antibiotic resistance using rectal swab cultures (targeted prophylaxis). We report our rates of infections and antibiotic resistance patterns during this period. From 2010 to 2016 we performed 2,398 transrectal prostate procedures. Overall there were 41 cases (1.7%) of infection related hospitalization. However, the rate differed significantly during the course of the study period. The infection related hospitalization rate declined from 3.8% to 1.1% in the first 3 years following the addition of intramuscular aminoglycoside (2011 to 2013), a decrease of 69%. In 2014 our infection rate increased to 2.6%, prompting the initiation of protocol 3, wherein the addition of target prophylaxis and formalin needle tip disinfection identified a 29.8% fluoroquinolone resistance rate and resulted in another decline in our infection rate to 1.2% (a decrease of 53%). While the initial addition of intramuscular aminoglycoside appeared to be effective in decreasing post-procedure infections, further augmentation of our prophylaxis regimen through rectal swab screening of high risk patients and formalin needle tip disinfection led to an additional decline in rates of infection related hospitalizations.